Targeting a specific protein interaction to address neurodegeneration in Alzheimer's disease
Official title: Immunomodulatory ligand B7-1 targets p75 neurotrophin receptor in neurodegeneration
Funded at Weill Medical Coll of Cornell Univ · NIH-10660332 · Data updated 2026-11-12
This study is looking at how a specific protein interacts with a receptor in the brain to understand its role in Alzheimer's disease, with the hope that this knowledge could lead to new treatments to help improve brain health for people with the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $2,345,480 |
| NIH project number | 1RF1AG078613-01A1 |
| Project ID | NIH-10660332 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are experiencing symptoms of Alzheimer's disease or related dementias.
✕Less likely to help
Patients with neurodegenerative conditions other than Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates how the immunomodulatory ligand B7-1 interacts with the p75 neurotrophin receptor in the context of neurodegeneration, particularly in Alzheimer's disease. The study aims to understand the role of this interaction in the aging brain, where an imbalance of inflammatory responses can lead to cognitive decline. By using advanced protein interaction techniques, researchers will explore how manipulating this interaction could potentially alter neuronal health and function. The findings may lead to new therapeutic strategies that could improve outcomes for patients with Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that slow down or reverse cognitive decline in Alzheimer's patients.
How similar studies have gone: Previous research has shown promising results in targeting similar protein interactions for neurodegenerative diseases, indicating potential for success in this novel approach.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Hempstead, Barbara L — Weill Medical Coll of Cornell Univ
- Study coordinator: Hempstead, Barbara L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.